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Hypertriglyceridemia (HTG) is a heritable risk factor for cardiovascular disease. Investigating the genetics of HTGmay identify new drug
targets. There are ~35 known single-nucleotide variants (SNVs) that explain only ~10% of variation in triglyceride (TG) level. Because of
the genetic heterogeneity of HTG, a family study design is optimal for identification of rare genetic variants with large effect size because
the same mutation can be observed in many relatives and cosegregation with TG can be tested. We considered HTG in a five-generation
family of European American descent (n ¼ 121), ascertained for familial combined hyperlipidemia. By using Bayesian Markov chain
Monte Carlo joint oligogenic linkage and association analysis, we detected linkage to chromosomes 7 and 17. Whole-exome sequence
data revealed shared, highly conserved, private missense SNVs in both SLC25A40 on chr7 and PLD2 on chr17. Jointly, these SNVs
explained 49% of the genetic variance in TG; however, only the SLC25A40 SNV was significantly associated with TG (p ¼ 0.0001).
This SNV, c.374A>G, causes a highly disruptive p.Tyr125Cys substitution just outside the second helical transmembrane region of
the SLC25A40 inner mitochondrial membrane transport protein. Whole-gene testing in subjects from the Exome Sequencing Project
confirmed the association between TG and SLC25A40 rare, highly conserved, coding variants (p ¼ 0.03). These results suggest a
previously undescribed pathway for HTG and illustrate the power of large pedigrees in the search for rare, causal variants.Introduction
Cardiovascular disease (CVD) is the leading cause of death
in the United States and poses a significant morbidity and
cost for treatment after cardiac events. CVD is associated
with the correlated traits of high LDL, low HDL, high total
cholesterol, high triglyceride (TG) (defined as 200 %
TG < 500 mg/dl in adults1), hypertension, diabetes, and
metabolic syndrome. Furthermore, CVD is associated
with environmental variables that can be confounded
with lipid levels, such as obesity, poor diet, lack of exercise,
and smoking.
Hypertriglyceridemia (HTG), defined as TG > 500 mg/dl
in adults,1 is a risk factor for CVD, independent of high
LDL and low HDL.2–7 Although HDL and TG levels are
highly correlated, an independent role of HDL level in
CVD etiology has been challenged by recent Mendelian
randomization studies and the failure of cholesteryl ester
transfer protein inhibitors to reduce vascular events.8,9
Conversely, Mendelian randomization suggests a causal
role of TG in CVD.10 Elevated TG has been implicated in
both microvascular and macrovascular endothelial
damage with associated atherosclerosis.6 Within the
United States, ~16% of adults of European origin have
high TG levels, indicating a need for further interven-
tion.7 However, studies of TG level and lipid metabolism
have been difficult.6,7 One reason for this difficulty is the
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is also associated with high LDL and low HDL, making it
difficult to tease apart the effect of specific lipids on CVD
risk within studies.
There are currently few pharmacological treatments for
elevated TG. The most common treatment, fibrates,
effectively reduces elevated TG and reduces the risk for
cardiovascular events.11,12 Unfortunately, some 5% of
individuals stop using fibrates because of side effects.13
Other potential drugs, targeting different parts of the
metabolic pathway, have been found to have intolerable
complications such as fatty liver or to actually raise the
risk of cardiovascular events.13
In order to find additional effective treatments, studies
of TG need to be undertaken. Focusing on the genetic con-
trol of elevated TG may remove some of the confounding
with LDL and HDL and lead to new drug targets. TG is
known to be heritable and there are several known genetic
mutations that influence TG levels, most notably those in
the structural loci for ApoA5 and ApoC3.14–21 In mice,
expression of both Apoa5 and Apoc3 are associated with
TG levels.22–25 Whereas circulating levels of ApoA5 are
negatively associated with TG levels, ApoC3 levels are
positively correlated with TG. However, there is conflicting
evidence in humans for an association between CVD and
single-nucleotide variants (SNVs) within APOC3 (MIM
606368) and APOA5 (MIM 107720).26–30 These and other
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variation in TG,20,21 which may explain the conflicting
evidence indicating a relationship between regulatory
SNVs and CVD.
The genetic heterogeneity in the etiology of high TG
makes large family studies the optimal design for identifi-
cation of novel TG loci with large effect sizes.31 This design
allows for the study of numerous people with an identical
mutation and the ability to study cosegregation as well as
association. For these reasons, we set out to discover genes
underlying elevated TG in a single large family, described
as familial combined hyperlipidemia (FCHL [MIM
144250]) in the 1980s and resampled in the 2000s,
yielding five generations, four of which have phenotype
and marker data. FCHL is genetically heterogeneous and
characterized by variable atherogenic lipoprotein levels
in multiple family members,32–35 making it an ideal diag-
nosis to identify novel lipid level genes. This family
includes four related individuals, including the proband,
with TG measurement in the top 1/2 percentile of adults
in the United States,36 and previously reported genetic
variation associated with TG does not explain the elevated
levels. Segregation analyses supported at least one major
gene for high TG in this family.
By using linkage analysis and whole-exome sequence
data, we detected two candidate genes of interest.
Although whole-exome sequencing has proven powerful
in discovering underlying loci for simple Mendelian traits
and de novo mutations, it has not yet been as successful
in uncovering major contributing loci to complex traits.
With family data, we have the opportunity to observe
the same very rare variant in multiple family members
and to evaluate cosegregation of a single variant with a
phenotype. In this paper, we show that reduction of the
search space by using linkage analysis in a large family,
and then focusing on rare exome variants, can be used to
successfully discover multiple major contributing loci for
a heterogeneous, complex quantitative trait. This allows
single gene burden testing in a second cohort, eliminating
the need for multiple gene tests, which increases the power
to detect an association.Subjects and Methods
Subjects and Phenotype
The family presented here was ascertained in the 1980s as part of a
cohort of four families of European American descent that had the
diagnosis of FCHL. Observed TG in these families was previously
shown to be associated with increased risk of CVD mortality.37
The proband had fasting triglycerides >2,900 mg/dl38 and normal
LDL-C levels. The family was subsequently ascertained and diag-
nosed with FCHL, based on hypertriglyceridemia and hypercho-
lesterolemia in first-degree relatives. The proband was originally
hypothesized to represent a homozygote for FCHL, thought to
be a Mendelian trait at that time. Re-collection of samples as
well as sampling of additional family members, particularly in
the youngest generation, took place in the 2000s. The final pedi-
gree contains 5 generations of 121 individuals and includes five1036 The American Journal of Human Genetics 93, 1035–1045, Decelarge sibships (n ¼ 5, 5, 6, 7, and 9). Fasting TG was measured
on 85 individuals (74 in the 1980s and 41 in the 2000s) via stan-
dard enzymatic methods, and reported in mg/dl.39 The same
methods were employed in the 1980s and 2000s. TG ranged
between 22 and 2,926 mg/dl, with a median of 111 mg/dl for
individuals not taking statin drugs. Twenty-six family members
had TG > 200 mg/dl and 8 had TG > 500 mg/dl. Four related
subjects in the second and third generations had TG > 1,000
mg/dl, making this family a good candidate for linkage analysis.
In addition, none of the subjects were taking lipid-lowering med-
ications in the 1980s and only nine were taking such medication
in the 2000s. All subjects, or their representative, gave written,
informed consent and this study was approved by the University
of Washington Human Subject Review Board (FWA #00006878).TG Adjustment
Fasting TG level is a highly right-skewed phenotype that is associ-
ated with age, sex, and body mass index in typical European
American populations. Because of the ascertainment, the TG in
this data set does not follow typical distributions and adjusting
the TG via a linear model with the family data would not result
in a reliable phenotype. To increase the power to detect linkage,
we corrected for this ascertainment by adjusting TG (adjTG) by
using the age- and sex-based means and standard deviations
from The Lipid Research Clinics Population Studies Data Book,
Volume 1,40 added the constant 8 to avoid negative values, and
then log transformed the data (log-adjTG) to reduce skew.
Because TGwasmeasured in the 1980s and 2000s for 30 individ-
uals, we generated three overlapping phenotype data sets. Data set
‘‘1980only’’ contains phenotypes from the 1980s only (n ¼ 74, all
statin-free). Data set ‘‘1980plus’’ contains phenotypes from the
1980s and phenotypes for only the newly sampled individuals
from the 2000s who are not taking lipid-lowering medications
(n ¼ 85 statin-free). Data set ‘‘2000plus’’ contains all phenotypes
from the 2000s for individuals not taking lipid-lowering medica-
tions and phenotypes from the 1980s for individuals who only
have phenotype at this time point or who were taking statin drugs
in the 2000s (n ¼ 85 statin-free). Phenotypes in data sets 1980plus
and 2000plus differ for 21 individuals.Genotyping
The family was extensively genotyped via highly polymorphic
markers, common SNVs, and next-generation exome sequencing.
Quality control on all genotype data as well as alignment to the
Rutgers Build 35 map was performed as described previously.41,42
In brief, STR markers from Marshfield Panel 9 (1980s), Prevention
Genetics Set 13 (2000s), and selected regions from Decode (1980s
and 2000s) were genotyped in the family (n ¼ 82). In addition,
~50K SNVs from the Illumina HumanCVD Bead chip were geno-
typed in the family (2000s, n ¼ 64).43 Finally, the exome was
sequenced on the Solexa platform for 16 individuals selected for
their phenotypes and informativeness for imputing the genotypes
of others.41,44 Novel SNVs of interest, detected with exome
sequencing, were genotyped in the entire pedigree via custom
TaqMan Genotyping Assays with the Applied Biosystems
7900HT real-time PCR system45 or Veracode 384-plex Bead
Plates.46Joint Segregation and Linkage Analysis
Given that log-adjTG is a complex trait with an unknownmode of
inheritance in these data, we used an iterative Bayesian oligogenicmber 5, 2013
Table 1. Percent Variance of log-adjTG Explained in the Family, by Previously Reported SNVs
Chr Gene (SNV, Proxy) MIM # SNV Proxy % Vtot (SD) % Vg (SD) p Value
1 DOCK7 604774 rs2131925 rs1748195 3 (3) 14 (16) 0.84
1 GALNT2 602274 rs1321257 rs4846914 4 (3) 23 (20) 0.15
2 APOB 107730 rs1042034 NA 4 (3) 16 (17) 0.73
2 GCKR 600842 rs1260326 NA 4 (3) 18 (19) 0.09
3 MSL2,a PCCB 614802, 232050 rs645040 rs3821445 3 (2) 17 (19) 0.34
4 AFF1 159557 rs442177 rs3775214 2 (2) 13 (17) 0.68
7 TBL2 605842 rs17145738 NA 5 (4) 20 (18) 0.04
8 LPL,a LPL 609708 rs12678919 rs12679834 2 (2) 14 (19) 0.64
8 TRIB1a 609461 rs2954029 rs17321515 3 (2) 13 (16) 0.60
10 CYP26A1a 602239 rs2068888 rs4418728 4 (3) 24 (21) 0.25
11 FADS1, FADS2 606148, 606149 rs174546 rs1535 3 (2) 14 (18) 0.82
11 APOA5 606368 rs3135506 NA 2 (2) 14 (18) 0.67
15 LIPC 151670 rs6074 rs871804 4 (3) 18 (17) 0.17
15 LIPC 151670 rs261342 NA 2 (2) 15 (19) 0.94
16 CTF1a 600435 rs11649653 NA 3 (3) 14 (16) 0.47
16 CETP 118470 rs7205804 rs1532625 3 (3) 21 (21) 0.99
19 APOE,a APOC1a 107741, 107710 rs439401 NA 5 (3) 20 (18) 0.12
19 SUGP1, GATAD2A 607992, 614997 rs10401969 rs3794991 1 (2) 10 (17) 0.70
20 PLTP 172425 rs4810479 NA 7 (5) 30 (18) 0.56
Estimated percent total variance (Vtot), percent genetic variance (Vg), and p value for pedigree adjusted association of log-adjTG and known or suspected
pathogenic SNVs in the family. Proxy SNVs from the CVD chip were used in place of the reported SNVs that did not exist on the CVD chip. Proxy SNVs are corre-
lated with the original SNV (r2 > 0.8). APOA5 (rs3135506) was genotyped separately in the family. The second column from left gives the gene name for the SNV
and its proxy, if necessary. Gene names are from NCBI and aliases are as follows: DOCK7 ¼ ANGPTL3, AFF1 ¼ KHL8, TBL2 ¼MLXIPL, SUGP1 ¼ CILP2. SD indicates
standard deviation.
aSNV is near but not within a gene.joint segregation and linkage analysis approach from the package
Loki2.4.7.47 This approach has many advantages for these data.
First, Loki is capable of handling multipoint analysis on a large
pedigree. Second, the user does not supply a trait model; rather,
a prior distribution on the genetic effects is supplied, allowing
the trait model, including the number of QTLs, to vary within a
plausible model space. Third, missing trait-locus genotypes can
be sampled at each iteration, given the marker segregation in the
pedigree. Fourth, genotype covariates can be included in the
model, allowing for estimation of the genetic variation explained
by a SNV at each iteration, including the information from the
estimated missing genotypes. Over an entire run, the average total
variation (Vtot) and genetic variation (Vg) explained can then be
used to estimate the percent Vtot and Vg explained by that SNV.
In addition to modeling the possibility of multiple QTLs, variance
resulting from any polygenic effects is captured by Vg. Because
calculating p values is time consumingwith thismethod,we calcu-
lated the Bayes factor (BF) for 2 cM intervals across the genome,
which compares the posterior odds to the prior odds that a QTL
is located in the region. We consider a maxBF > 25 as suggestive
of linkage.41,48 All identified linkage regions were jointly analyzed,
allowing the regions to compete for the modeled QTLs.
Because the trait under study is skewed, it is important to specify
a prior distribution that is expansive enough to include a likely
model but not so broad that the space cannot be adequatelyThe American Jousampled. Furthermore, the detected regions of linkage should be
consistent given differing prior distributions. By using methods
described previously,49–51 we used several values for the under-
lying additive genetic effects, ranging between 1 and 8 times the
standard deviation (SD) of log-adjTG in order to verify consistency
of detected linkage regions. Here we report the results for the prior
distribution with mean additive genetic effect ¼ 2.7 times the SD
of log-adjTG. All runs contained 1,000 burn-in iterations followed
by 200,000 iterations (1 chromosome) or 500,000 iterations
(2 chromosomes jointly), of which every 10th iteration was saved.
The prior distribution on the number of QTLs followed a curtailed
Poisson(1) distribution with a maximum of 15. The total map
length was assumed to be 3,000 cM. The prior distribution on
the allele frequency for all QTLs is set to Uniform(0,1) and cannot
be changed by the user.Candidate Locus Analysis
Candidate loci were assessed for the estimated percent Vtot and Vg
that they explained in the family. These candidate variants were
chosen from two sources (Tables 1 and 2 and Table S1 available
online). First, candidate SNVs known or thought to be associated
with TG,21,52 including APOA5 variant rs3135506, were assessed
within the family primarily via the CVD chip data. If the reported
SNV was not on the CVD chip, we attempted to find a correlatedrnal of Human Genetics 93, 1035–1045, December 5, 2013 1037
Table 2. Distribution of Novel SNVs under the Linkage Signals on
Chr7 and Chr17
Chr. 7 17
# novel sites 53 20
Intergenic 2 1
Intronic 4 1
30 UTR 1 1
50 UTR 1 0
Synonymous 23 2
Splice 0 1
Missense 22 14
GERP > 3 12 6
Shared 1 4
Liver expressed 1 2
The final row indicates the number of novel SNVs that are missense or splice
sites, have Genomic Evolutionary Rate Profiling score (GERP) > 3, and are
shared by at least two relatives with high log-adjTG. Novel is defined as not
existing in dbSNP134.proxy SNV (r2 > 0.8) within 500 bases of the reported SNV.53,54
APOA5 SNV rs3135506 was genotyped separately. A Bonferroni
adjustment was used for the testing of these known candidate loci.
Candidate rare SNVs were chosen from the exome data in the
linkage regions. Exome sites were filtered based on novelty, coding
effect, conservation across mammals, and sharing of the rare allele
among the four individuals with TG > 1,000. Because the genetic
basis of TG in this family had yet to be discovered, we hypothe-
sized that the high levels of TG were due to novel variation. We
defined a variant as novel if it did not have an rsID in dbSNP134
at the time of exome sequencing (April 2012)55 and occurred at
most once in the NHLBI Exome Sequencing Project (ESP) data
on 6,500 exomes. Only sites that had an effect on the coding
sequence (nonsense, missense, or splice) were kept. Conservation
acrossmammals was calculated by the Genomic Evolutionary Rate
Profiling (GERP) score;56 positive values indicate conservation and
negative values indicate lack of conservation. Only sites with a
GERP > 3 were considered because we expect only mutations at
locations with high conservation across mammals would be path-
ogenic for high TG. Finally, the rare allele had to exist in at least
two of the four individuals with TG> 1,000. All pedigreemembers
were genotyped for the novel sites selected with these criteria to
confirm their estimated effect. Variance components analysis in
the package SOLAR57 was used to calculate p values for associa-
tion, in a mixed model analysis that adjusted for correlation
among related individuals through the kinship matrix, which
captures any underlying shared polygenic effect.
Validation of Novel Gene Association
We sought confirmation of association with TG for any gene con-
taining a novel SNV that remained associated with the trait after
genotyping of the full pedigree. By using TG data from unrelated
individuals in the PennCATH, TRIUMPH, Cleveland Clinic,
ARIC, CARDIA, CHS, FHS, JHS, MESA, and WHI cohorts in the
dbGaP posted ESP data, we combined all rare (MAF < 0.5%)
missense, nonsense, and splice SNVs with GERP> 4.8 into a single
genotype factor (1 ¼ presence of a minor allele and 0 ¼ absence of1038 The American Journal of Human Genetics 93, 1035–1045, Deceall minor alleles) in individuals with measured TG. We used a
GERP cutoff of 4.8 because this is the 75th percentile for GERP of
all identifiable LDL-raising pathogenic SNVs in LDLR (MIM
606945)55,56,58,59 (data not shown). We assumed that individuals
missing genotypes at these rare SNVs were noncarriers. We per-
formed this two-sided whole-gene test via a linear model for
log(TG) on the {0, 1} genotype factor, using the package R with
and without adjusting for race (first three principal components
or ethnic group), age, and sex. Statin and fibrate usage is not
contained in this data. However, because thesemedications reduce
TG levels, their absence from the model serves to make the test
more conservative.Results
Phenotype
The adjTG is a stable phenotype over time in this data set.
The correlation of adjTG values ~20 years apart, in the 21
individuals with data at both time points and not on
statins, is highly significant (r2 ¼ 0.78, p ¼ 2.7 3 105)
with positive slope coefficient (b ¼ 0.5). adjTG level
appears to have larger variance at higher levels, as
expected. The adjusted values were independent of age
and sex, as expected.Known TG SNVs
There were 18 SNVs, or their proxies, on the CVD chip of
the total 35 (Table 1) that were reported to have an effect
on TG.21,52 These 18 SNVs and the APOA5 SNV,
rs3135506, explained at most 7% Vtot in log-adjTG in
this family (Table 1). In addition, there was no association
with the cumulative genetic risk score21 and log-adjTG
(p ¼ 0.20). rs4810479, in the 50 region of PLTP (MIM
172425), explained the most Vtot in log-adjTG, 7%
(SD ¼ 5%), but was not significantly associated with
log-adjTG (p ¼ 0.56), adjusting for pedigree structure.
The APOA5 SNV, rs3135506, explained 2.1% Vtot (SD ¼
2%). SNV rs17145738 in TBL2 ([MIM 605842] alias
MLXIPL) and near one of our linkage signals (see below),
explained 5% Vtot in log-adjTG (SD ¼ 4%) and had the
lowest p value for association, p ¼ 0.04, adjusting for
pedigree structure. This result is not significant given the
Bonferroni adjustment for multiple testing (Bonferonni
cutoff of 0.003). Furthermore, theminor allele is associated
with lower log-adjTG, indicating that this common SNV is
unlikely to explain the high TG observed in this family.
Because these known SNVs did not explain much of the
Vtot in log-adjTG and were not significantly associated
with log-adjTG, we performed linkage analysis to identify
regions of interest.Joint Segregation and Linkage Analysis Results
Segregation analysis, both alone and in conjunction with
linkage analysis, shows evidence of at least one QTL under-
lying log-adjTG. Given the prior mean additive genetic
effect ¼ 2.7 times the SD of log-adjTG, the posterior prob-
ability of at least one QTL is 0.97, 0.88, and 0.998 for datamber 5, 2013
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Figure 1. Evidence of Linkage, as
Measured by the Bayes Factor, on Chro-
mosomes 7 and 17 for the Three Data
Sets 1980only, 1980plus, and 2000plus
Location is given in cM and spans
the entire length of the chromosomes.
The horizontal dashed line at 25 in-
dicates the cutoff for evidence for linkage.sets 1980only, 1980plus, and 2000plus. The posterior
probability of exactly one QTL is 0.83, 0.54, and 0.23 for
data sets 1980only, 1980plus, and 2000plus. In addition,
the three overlapping data sets show support for log-adjTG
linkage to chr7 and chr17 (Figure 1). Data sets 1980only
and 1980plus support linkage to both chromosomes.
Data set 2000plus shows support for only chr17. Using
differing prior distributions on the genetic effects did not
change the locations of the linkage signals (data not
shown). Because data set 1980plus shows support for
both regions and contains more phenotype data than
does 1980only, we continued the analysis with this data
set. The posterior predicted model for 1980plus is a reces-
sive mode of inheritance.
Novel SNVs
Within and near these linkage regions, we found five novel
SNVs that met our criteria for candidacy, labeled N7, N17a,
N17b, N17c, and N17d, that were private to this family
(Tables 2 and 3). Variant N7 is shared by all four IDs with
TG > 1,000. Although chr17 contained four SNVs of
interest, they were shared by three different pairs of IDsTable 3. Percent Variance of log-adjTG Explained in the Family, by Candidate Novel SNVs
Variant N7 N17a N17b N17c
Chr 7 17 17 17
Pos. 87477251 4711152 6021379 2290581
Gene SLC25A40 PLD2 WSCD1 MNT
RefSeq NM_018843.3 NM_002663.4 NM_015253.1 NM_0203
NT change c.374A>G c.85A>T c.1246A>G c.1363G>
Protein change p.Tyr125Cys p.Thr29Ser p.Arg416Gly p.Val455L
Coding effect missense missense missense missense
GERP 5.1 5.1 4.3 3.9
%Vtot as exome variant 19 7.8 4.8 5.3
%Vg as exome variant 49 23 22 27
maxBF 1.8 48 103 72
Estimated percent total variance (Vtot) and genetic variance (Vg) in log-adjTG explained by each of the cand
only individuals that have exome data. MaxBF are given for when the novel variant is included as a marker
analysis. Missing genotype data are imputed for other family members. Physical positions are from build 37
N17b, N17c, and N17d as follows: N17b ¼ rs200724890, N17c ¼ rs201365025, N17d ¼ rs202160684. Th
it has two isoforms.
The American Journal of Human Geneticswith TG > 1,000: N17a at one pair,
N17b at another, and N17c and
N17d at a different pair. These fiveSNVs explain 19%, 7.8%, 4.8%, 5.3%, and 5.3% of Vtot,
respectively, in data set 1980plus. It is expected that the
estimated %Vtot explained will decrease upon full geno-
typing in the family, because the most informative people
have measured or imputable genotypes and the branch of
the family without variability of the SNV of interest will
lower the Vtot explained. Therefore, we chose to pursue
full genotyping of N7 and N17a only because they
explain>7% of Vtot with just the exome genotypes, which
is more than the known SNVs in PLTP, APOA5, and TBL2
noted above. These SNVs were in SLC25A40 (MIM
610821) and PLD2 (MIM 602384), respectively. Addition-
ally, no known pathogenic or novel likely pathogenic
variation was found in the known TG genes LPL (MIM
09708), APOC2 (MIM 608083), APOA5, GPIHBP1 (MIM
612757), and LMF1 (MIM 611761) or in the lipid-related
genes CETP (MIM 118470) and LDLR in the 16 exomes.
Jointly analyzing the chromosomes and their associated
novel SNVs, genotyped in the full family, clarifies the
relationship among these two regions (Figures 2 and S1).
As expected, given the complex model, adjustment for
each SNV impacts the linkage evidence for the other region.N17d
17
4496467
SMTNL2
10.2 NM_001114974.1; NM_198501.2
C c.730þ1G>T; c.298þ1G>T
eu NA
splice
5.0
5.3
27
66
idate novel SNVs within the linkage regions, using
and covariate in the joint linkage and association
. In dbSNP137, rsIDs have been assigned to SNVs
ere are two RefSeq numbers for SMTNL2 because
93, 1035–1045, December 5, 2013 1039
 5
 15
 25
 35
 0  50  100  150  200
B
ay
es
 F
ac
to
r
Location (cM)
+ chr. 17
cov. N7
cov. N17
chr 07
 100
 200
 300
 0  20  40  60  80  100  120  140
Location (cM)
chr 17
+ chr. 07
cov. N7
cov. N17
Figure 2. Evidence of Linkage in Data Set
1980plus, as Measured by the Bayes
Factor, on Chromosomes 7 and 17 when
Analyzed Jointly, and with either SNV N7
or N17 as a Genotype Covariate
Location is given in cM and spans the
entire length of the chromosomes. The
horizontal dashed line at 25 indicates
the original cutoff for evidence for linkage.When both chromosomes are analyzed jointly, the linkage
evidence on chr7 was reduced (maxBF¼ 8), but the linkage
to chr17 remained (maxBF ¼ 207). Linkage results are
similar when including the fully genotyped SNVs N7 and
N17a as markers only, in the analysis, indicating that
when neither of the SNVs is included as a genotype covar-
iate, the posterior distribution favors chr17 over chr7.How-
ever, only SNVN7 explained all evidence for linkage (chr17
maxBF reduced from 207 to 1, and chr7 maxBF reduced
from 8 to 0.5) when included as a genotype covariate
(Figure 2). When included as a genotype covariate, N17a
explained some of the signal on chr17 (maxBF decreases
from 207 to 69) and chr7 (maxBF reduces from 8 to 3.5).
The relative strength of each candidate SNV is reflected
in the percent Vg explained by each, as well as the signifi-
cance of the pedigree-adjusted association with log-adjTG.
N7 (Ngt¼ 40) explained 19% of log-adjTGVtot and 49% of
Vg. N17a (Ngt ¼ 78) explained 7% of log-adjTG Vtot and
25% Vg. When both variants are included jointly, they
explained 49% of log-adjTG Vg; with N7 and N17a
explaining 40% (p ¼ 0.0001) and 8.6% (p ¼ 0.31) of log-
adjTG Vg, respectively. We also explored the significance
of the known TG SNVs while adjusting for N7 genotype.
In this case, each SNV explained <5% of Vtot and were
not statistically significant (unadjusted p > 0.08). The
TBL2 SNV remained insignificant (unadjusted p ¼ 0.08).
Furthermore, this SNV is carried by individuals with
log-adjTG below the mean, and these are not the same
individuals as those that carry the N7 variant. Although
N7 is associated with log-adjTG, it is not associated with
LDL-C in this family (p ¼ 0.83, Figure S2).Table 4. Demographic Count Data and Age Distribution for the
ESP Cohort, Broken down by Quantile of log(TG)
Log(TG) quantile M F EA AA Mean (Min, Max) Age
[1.77,4.36] 341 597 434 504 50.15 (12, 85)
(4.36,4.74] 298 666 461 503 57.60 (18, 84)
(4.74,5.13] 312 596 522 386 58.27 (20, 93)
(5.13,6.84] 343 589 664 268 59.69 (21, 90)
This data set contains 3,770 verified unrelated individuals. Abbreviations are as
follows: M, male; F, female; EA, European American; AA, African American.
1040 The American Journal of Human Genetics 93, 1035–1045, DeceConfirmation of SLC25A40 Association
SLC25A40 was significantly associated with log(TG) in a
separate cohort by using ESP data (Table 4). There were
five rare missense SNVs (Table 5) in SLC25A40 with
GERP > 4.8 identified in ESP subjects with TG data.
Notably, the SLC25A40 SNV in the linkage family had
a GERP of 5.1 and each of these five SNVs had
GERPs > 5.1; two were predicted to be ‘‘probably
damaging’’ by PolyPhen.60 Six subjects of European
American (EA) descent and two of African American (AA)
descent carried one of these variants. The two of AA
descent carried the same SNV; this SNV did not vary in
EA in the entire ESP data. The SNVs found in the EA-
descent subjects were also specific to that ancestry group.
No subject carried more than one of these SLC25A40
SNVs. After pooling carrier status for each of these SNVs
into a single factor, the whole-gene test gives a significant
positive association between these high GERP variants at
SLC25A40 and log(TG) (b ¼ 0.45, two-sided p ¼ 0.02),
adjusted for age and sex. This whole-gene association
with log(TG) remains significant and positive when
adjusted for race, age, and sex (b ¼ 0.42, two-sided
p ¼ 0.03). Results are similar when applied to individuals
older than 25 and when removing individuals with a rare
SNV in the gene, whose GERP score ranges between 2
and 4.8. Although the sample size is too small for stratified
testing, the coefficient is positive in both ancestry groups
(b ¼ 0.18 and 1.1 for EA and AA descent, respectively).
Although we focused on SLC25A40 as the best candidate
from this region, we sought to rule out associations of
other regional genes and log(TG) in the ESP cohort by
similar analyses (Table S2). Carrier status at PLD2 (p ¼
0.48), WSCD1 (p ¼ 0.19), MNT (p ¼ 0.81 [MIM 603039]),
and SMTNL2 (p ¼ 0.87) did not predict log(TG).Discussion
We identified two genes, SLC25A40 and PLD2, each con-
taining a novel variant that cosegregates with severely
high TG levels in a single large family ascertained for segre-
gation of FCHL. Joint analysis of the linkage regions and
these variants indicated that the variant in SLC25A40 is
the most probable variant for pathogenicity. However, wember 5, 2013
Table 5. Rare SNVs with GERP > 4.8 in SLC25A40 Found in Individuals in the ESP Data
Position rsID NT Change MAF % (EA/AA/All) AA Change GERP PolyPhen n
87470986 NA c.785A>G 0.0118/0.0/0.0078 p.Gln262Arg 5.92 B 1 EA
87483601 NA c.182G>T 0.0/0.0454/0.0154 p.Gly61Val 5.91 PD 2 AA
87473169 rs145515966 c.641G>C 0.0117/0.0/0.0077 p.Trp214Ser 5.67 PD 1 EA
87473143 rs140104130 c.667T>A 0.0349/0.0/0.0231 p.Trp223Arg 5.67 B 3 EA
87477276 NA c.349G>A 0.0116/0.0/0.0077 p.Ala117Thr 5.13 B 1 EA
MAF % based on 8,600 European (EA) and 4,406 African American (AA), self-reported ancestry subjects; TG were measured in 2,168 EA and 1,793 AA subjects,
with ancestry genetically verified. Abbreviations are as follows: B, benign; PD, probably damaging.cannot rule out a possible interaction or additive effect
between these and other identified variants. No known
common pathogenic variants were found to be associated
with TG in this family. We were able to replicate the effects
of rare, conserved missense mutations only in SLC25A40
in the separate ESP cohort.
SLC25A40 is solute carrier family 25, member 40, and its
product localizes to the mitochondria, where it is involved
in membrane transport.61 Although the gene is ubiqui-
tously expressed, its product is foundmainly in the adrenal
gland.62 The novel variant in this gene (RefSeq accession
number NM_018843.3), c.374A>G, is located in the
seventh exon (of 12), is highly conserved (GERP ¼ 5.1),
and causes a p.Tyr125Cys substitution in the 338 amino
acid protein. This change is just outside the second helical
transmembrane region of the protein. Although there is no
PolyPhen prediction, the tyrosine at amino acid 125 is
perfectly conserved across vertebrates.58,63 Furthermore,
the Grantham score is 194, indicating a high chemical
dissimilarity from the wild-type.64 This particular muta-
tion causes a new cysteine that neighbors a cysteine at
position 124 and increases the number of cysteines to 9.
Cysteines play a critical role in protein folding because
they are the only amino acids that can create disulfide
bonds that stabilize the folded form of the protein.65
This change of a single amino acid to a cysteine allows
for an increased number of folding possibilities, and
possibly a lower entropy stabilization, which can disrupt
the protein’s function.
It is possible that this specific variant is not pathogenic,
but is in linkage disequilibrium with a causal variant
not detected by our exome sequencing. Further gene
sequencing, as well as functional studies, are needed to
verify the association. However, we found evidence for a
pathogenic effect of high TG for rare, conserved
(GERP > 5) missense variants in SLC25A40 in a separate,
unrelated cohort, supporting the idea that SLC25A40
affects TG levels.
Although our analyses suggest that a PLD2 missense
variant may also impact TG, whole-gene testing in a sepa-
rate cohort does not support pathogenicity for the gene.
Further study may be warranted, because this gene may
have biological relevance to TG. PLD2 is phospholipase
D2, whose product catalyzes the hydrolysis of phosphati-The American Joudylcholine to phosphatidic acid and choline, and is ubiq-
uitously expressed. The novel variant in this gene (RefSeq
NM_002663.4), c.85A>T, causes a p.Thr29Ser (out of 934
amino acids) and is highly conserved across mammals.
Three other candidate genes identified on chr17,
WSCD1, MNT, and SMTNL2, also were not significantly
associated with TG in this separate cohort. Of these three
genes, only SMNTL2 is expressed in liver. SMNTL2 is
smoothelin-like 2, of which very little is currently known.
Because neither WSCD1 nor MNT are expressed in liver,
they are less likely to be involved in TG regulation. Little
is known about WSCD1, the WSC domain containing 1
gene. MNT encodes the MAX dimerization protein and is
thought to repress transcription by binding to DNA bind-
ing proteins.66,67 Reliance on the exome-sequence data
rather than full-genome sequencing may have missed
other potentially causal variants.
It is worth noting that the size of the linkage signals do
not necessarily correlate with the candidate gene with the
most evidence for causality. When chr7 and chr17 are
analyzed jointly, the posterior distribution prefers a reces-
sive QTL with moderate allele frequency on chr17. This
is most probably due to the ascertainment scheme, lack
of prior information on the allele frequency, and the
observed phenotype segregation. The ascertainment
scheme, which is useful for observing a rare allele multiple
times, artificially inflates the observed allele frequency. In
addition, the uniform prior distribution on the allele fre-
quencies does not allow for a preference for rare alleles.
Finally, the skew of the phenotype data in which offspring
may have much higher phenotype than their parents re-
sults in evidence for a recessive trait. Therefore, segregation
analysis showed overwhelming support for a recessive
gene with a common allele frequency, which fit themarker
and trait segregation at chr17. Further analysis including
the exome-sequence data as covariate effects, which
included a fixed rare allele frequency in the model, favored
a dominant gene as evidenced by the high association of
the SNV on chr7 with TG in the family.
The sampling and analysis design used here is a powerful
approach for successful identification of novel genes and
biological pathways underlying heterogeneous complex
traits. Ascertainment of a large family segregating extreme
values of a quantitative phenotype reduces the number ofrnal of Human Genetics 93, 1035–1045, December 5, 2013 1041
putative underlying highly penetrant loci, increasing the
chances of finding a variant with biological relevance in
multiple family members. The large size of the pedigree,
although a fraction of the size of a typical GWAS sample,
provides multiple dimensions of information that, when
used jointly, substantially increases the power to detect
linkage.31 Furthermore, correction for the ascertainment
of these extreme phenotypes, as in this study, further
increases power to detect linkage. The use of linkage
analysis further drastically reduces the search space,
limiting the multiple testing problem seen with GWASs
or exome-wide burden tests. Finally, joint linkage and asso-
ciation in such pedigrees, as when both chromosomes 7
and 17 compete for the modeled QTL and the candidate
novel variants are included as covariates, can help deter-
mine which of the identified candidate genes has the
most promise. One limitation of this approach is that the
same rare variant may not be found in a second family or
enough unrelated individuals to provide confirmation;
however, a single or limited number of gene-based burden
tests can be made in an unrelated sample, again avoiding
the penalty of exome-wide multiple comparisons.
Although common alleles have been found to explain a
small portion of moderate to severe HTG in unrelated
samples, we show that rare variation plays a major role
in explaining severe HTG in a family previously diagnosed
with FCHL and that this knowledge can be used to identify
novel genes and biological pathways of interest. Addition-
ally, our linkage results and the replication of a HTG effect
in the ESP data, which is not ascertained on FCHL, lend
support to an oligogenic inheritance of the lipid traits
contributing to the diagnosis of FCHL in this family.
Further evidence for this includes the fact that LDL-C level
is not associated with the SLC25A40 variant in these data,
the proband had normal LDL-C and apoB levels, we do not
detect linkage between LDL-C and this region of chr7 (data
not shown) by similar methodology, and we have previ-
ously reported linkage between apoB level and chr4 in
this family.42 FCHL families may not have a monogenic
disorder as earlier described, but rather a confluence of
separate traits in the same family. Furthermore, the com-
plex nature of the trait within this family is borne out by
the fact that three carriers of the SLC25A40 variant do
not have HTG, although two of them have TG near the
95th percentile (Figure S2), and that one individual with
TG > 500 does not carry the SLC25A40 variant, indicating
that other genetic variants may be influential. However,
the polygenic effects are accounted for in the analysis
and have a small impact on the trait, relative to the major
gene component. Indeed, SLC25A40 may be shown to
cause familial hypertriglyceridemia (MIM 145750), given
that it does not appear to raise LDL-C. We note that our
proband had highly elevated TG for a subject with FCHL,
which is why the proband was thought to potentially be
a FCHL homozygote; thus, the relationship of this locus
to a more typical FCHL family with more modest HTG is
not yet clear. Neither SLC25A40 nor PLD2 (or their respec-1042 The American Journal of Human Genetics 93, 1035–1045, Decetive biological pathways) have been previously implicated
in triglyceride levels, to our knowledge. Functional studies,
in vitro and in vivo, will need to be carried out to verify
that they impact TG levels and to discover the mechanism
by which they have an effect. Given the relevance of high
TG to CVD, TG-lowering treatments targeted to these
pathways may be identified.Supplemental Data
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